Restoring balance.
Renewing life.

Akero is pioneering novel therapies to transform the lives of people living with serious metabolic diseases.
Learn More
Learn More

Advancing Efruxifermin (EFX) for MASH

Our flagship EFX program is designed to be a differentiated, potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)

Learn more

Ongoing Clinical Studies

We have multiple ongoing clinical trials to evaluate our investigational drug, EFX, as a treatment for MASH.

Learn more

Recent Press Releases from Akero

02/28/2025

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

01/30/2025

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

01/28/2025

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

View All

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions